1132656-73-5

Basic information

• Product Name: (R)-Ostarine
• Synonyms: (R)-Ostarine;(R)-N-(4-Cyano-3-(trifluoroMethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-MethylpropanaMide;(R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropionamide
• CAS NO: 1132656-73-5
• Molecular Formula: C₁₉H₁₄F₃N₃O₃
• Molecular Weight: 389.3279696
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 1132656-73-5.mol

Chemical Properties

• Boiling Point: 632.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 12.13±0.29(Predicted)
• BRN: 21172990
• CAS DataBase Reference: (R)-Ostarine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Ostarine(1132656-73-5)
• EPA Substance Registry System: (R)-Ostarine(1132656-73-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1132656-73-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-Ostarine is used as a pharmaceutical agent for its potential therapeutic effects on muscle wasting, osteoporosis, and other conditions related to muscle and bone health. Its selective binding to androgen receptors allows for targeted treatment with fewer side effects compared to traditional anabolic steroids.
Used in Sports Nutrition Industry:
(R)-Ostarine is used as a sports supplement to enhance muscle growth, strength, and recovery. Its ability to selectively bind to androgen receptors makes it a popular choice among athletes and bodybuilders looking to improve their performance and physique without the risk of severe side effects associated with anabolic steroids.
Used in Research and Development:
(R)-Ostarine is used as a research compound for studying the effects of selective androgen receptor modulation on various physiological processes. This research can help in the development of new drugs and therapies for conditions such as muscle wasting, osteoporosis, and other muscle and bone-related disorders.

Upstream product

• 767-00-0 4-cyanophenol 
• 113181-02-5 (S)-(-)-3-bromo-2-hydroxy-2-methyl-N-[(4-cyano-3-(trifluoromethyl)phenyl)]propanamide 

Relevant articles and documents

Synthetic method of alpha-hydroxypropanamide derivatives with optical activity

The invention discloses a synthetic method of alpha-hydroxypropanamide derivatives with optical activity and belongs to the field of organic synthesis. Proline taken as a chiral auxiliary, as well asmethacryloyl chloride, is subjected to acylation, bromination and chiral auxiliary removal, a product and 4-cyano-3-trifluoromethylaniline are subjected to nucleophilic substitution, and 3-bromo-2-hydroxy-2-methyl-N-[(4-cyano-3-trifluoromethyl)phenyl]propanamide is obtained and subjected to nucleophilic substitution with 4-cyanophenol, and the compound 3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethylphenyl]-2-hydroxy-2-methylpropanamide with optical activity is prepared. 3-bromo-2-hydroxy-2-methyl propionic acid and 4-nitro-3-trifluoromethylaniline are subjected to aminolysis, a product is subjected to nucleophilic substitution with paracetamol, and the compound 3-(4-acetoxyphenoxy)-N-[4-nitro-3-(trifluoromethylphenyl]-2-hydroxy-2-methylpropanamide with optical activity is prepared. The efficient synthetic method of the alpha-hydroxypropanamide derivatives with optical activity is provided.

A METHOD OF TREATING ANDROGEN RECEPTOR (AR)-POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS)

This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; 1) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.